STOCK REPORT · 069620 · KOSPI
Daewoong Pharma
Star it to add it to your market report.
Overall grade
59 pointsMiddle bandOverall 59 points · Grade B, 11 points to Grade A
Financial summary
Daewoong Pharma (069620) has an overall grade of B from financial statements, with a score of 59 out of 100. Category scores are Earnings 77 (Grade A), Financial health 49 (Grade C) and Dividends 43 (Grade C). Data as of Oct 23, 2026.
Reported figures: ROE 17%, Operating margin 12.53%, Revenue growth +10.42%, Debt-to-equity ratio 108.24%, Current ratio 124.38%, Dividend yield 0.3%, Payout ratio 3.5%, Dividend streak 11 yrs. Valuation: PER 6.18x, PBR 1.05x, Market cap ₩1.2T.
8 of the 9 graded metrics have values in this update.
The earnings metrics come from the 2025 annual report filed with the Financial Supervisory Service of Korea (DART). The share price was collected from the Korea Exchange on Oct 23, 2026. PER and PBR divide the market cap by the year-end figures. How the grades are calculated is set out in the grading methodology.
This summary restates reported financial figures. It does not forecast share prices or returns.
Valuation
52-week range
Now at 1% of rangeWithin their own 52-week ranges, 3.3% of major Korean stocks sit lower than this one.
About these metrics
- PER
- Price to earnings ratio (market cap ÷ annual net profit). A lower value means a lower price relative to profit.
- PBR
- Price to book ratio (market cap ÷ net assets). Below 1x, the market value is below book value.
- Market cap
- Share price × shares outstanding. The value the market puts on the whole company.
- 52-week high
- The highest share price over the past year.
- 52-week low
- The lowest share price over the past year.
Scores by category
Each metric out of 100 · category score is the average of threeEarnings
40% of overall · Upper bandEach metric is scored out of 100, and the 77 above is the average of the three scores.
Metrics with values3 of 3
Fiscal year 2025 results
About these metrics
- ROE
- Return on equity. How much profit the company made on its own capital (equity).
- Operating margin
- Operating profit as a share of revenue: what the core business keeps.
- Revenue growth
- How much revenue changed compared with a year earlier.
Financial health
35% of overall · Lower-middle bandEach metric is scored out of 100, and the 49 above is the average of the three scores.
Metrics with values2 of 3
Metrics shown as - in the table are not measured in this update, because the data has no such item.
About these metrics
- Debt-to-equity ratio
- Liabilities as a share of equity. A lower ratio means the company relies less on debt.
- Current ratio
- Assets that can turn into cash within a year, as a share of debts due within a year. At 100% or more they cover those debts.
- Interest coverage
- How many times operating profit covers interest expense. Below 1x, operating profit does not cover interest.
Dividends
25% of overall · Lower-middle bandEach metric is scored out of 100, and the 43 above is the average of the three scores.
Metrics with values3 of 3
Fiscal year 2025 results
About these metrics
- Dividend yield
- Dividends paid over a year as a share of the current share price.
- Payout ratio
- The share of profit paid out as dividends. A very high ratio can be hard to keep up.
- Dividend streak
- How many years in a row the company has paid a dividend.
Metric scores are shown rounded to one decimal place, so a category score can differ by up to 1 point from a plain average of the three shown.
Strengths · Weaknesses
Strengths
- High profit relative to equity (ROE 17%)Above the median 9.2% of 63 Healthcare stocks
- Has paid dividends for 11 yrs in a row
- Share price is low relative to earnings (PER 6.18x)Below the median 34.3x of 52 Healthcare stocks
Weaknesses
No notable weaknesses among metrics with values
Only metrics that stand out as clearly good or weak against general benchmarks are listed. Where a comparison is possible, the position against the median of stocks in the same sector is shown too. The stock count on each sector line covers only stocks with that metric, so it differs by metric.
Metrics that moved the overall score
- ROE+5.1 pts
- Dividend streak+3.4 pts
- Revenue growth+3.1 pts
- Operating margin+2.8 pts
- Debt-to-equity ratio+0.1 pts
- Interest coverage0.0 pts
- Current ratio-0.3 pts
- Payout ratio-2.4 pts
- Dividend yield-2.7 pts
Metric scores run up to 100, and the middle score is 50. If all nine metrics scored 50, the overall score would also be 50. Each bar is the contribution of one metric: how far its score sits from the 50 baseline, converted by that metric weight. Right means it raised the overall score, left means it lowered it.
Adding the nine contributions above to the baseline gives 59.1 points, and this stock's overall score is 59. The overall score is calculated from unrounded metric scores and then truncated, while the contributions here are rounded to one decimal place, so the two can differ by up to 1 point. Metrics that are not measured values still carry a contribution, because their scores did go into the overall score and hiding them would hide part of the basis of the grade.
| Metric | Daewoong Pharma | Sector median | Rank in sector |
|---|---|---|---|
| PER | 6.2x | 34.3x | |
| PBR | 1.1x | 6.7x | |
| ROE | 17.0% | 9.2% | |
| Operating margin | 12.5% | 13.0% | |
| Debt-to-equity ratio | 108.2% | 54.9% | |
| Dividend yield | 0.3% | 0.7% |
Grey values on the right are sector medians
Metric ranks in sector
Closer to 1st sits further left- PERRank 1 of 52, top 2%
- PBRRank 1 of 65, top 2%
- ROERank 17 of 63, top 27%
- Operating marginRank 35 of 67, top 52%
- Debt-to-equity ratioRank 53 of 64, top 83%
- Dividend yieldRank 36 of 52, top 69%
On the rank strip, the left end is 1st. PER, PBR and debt-to-equity ratio are ranked from the lowest value, and ROE, operating margin and dividend yield from the highest.
Healthcare stocks close in market cap rank
Sector medians cover the 71 Healthcare stocks listed on Jupick. Typical levels differ by sector, so this is reference information for a simple comparison and not a basis for investment decisions.
About these metrics
- PER
- Price to earnings ratio (market cap ÷ annual net profit). A lower value means a lower price relative to profit.
- PBR
- Price to book ratio (market cap ÷ net assets). Below 1x, the market value is below book value.
- ROE
- Return on equity. How much profit the company made on its own capital (equity).
- Operating margin
- Operating profit as a share of revenue: what the core business keeps.
- Debt-to-equity ratio
- Liabilities as a share of equity. A lower ratio means the company relies less on debt.
- Dividend yield
- Dividends paid over a year as a share of the current share price.
Where this score sits
43.8% of the major stocks graded by Jupick score lower than this. Stocks in the same Grade B: 289.
- S172.8%
- A14524.2%
- BThis stock28948.2%
- C12621%
- D233.8%
The Grade B band runs from 50 to 69 points, 20 points wide. This stock's 59 points sit 9 points above the lower boundary, and 11 points remain to 70, where Grade A starts.
Within the Healthcare sector alone, it ranks No. 38 of 71 stocks with an overall score, and the median overall score of the sector is 60.
Unlike metric values, the overall score uses the same baseline for every market and currency, so Korean and US stocks share one sample. The grade boundaries of 85, 70, 50 and 30 points apply equally to every stock, so the counts above are how the sample actually splits at those boundaries. Because one point can decide a grade, two stocks with different grades can be closer in score than two stocks with the same grade. The shares and ranks here describe only the major stocks Jupick covers, not every listed stock.
Schedule
Dividend dates
Payment date: not in the free data Jupick uses. This does not mean the company has not set a date. How often each date is missing is counted separately.
- Ex-dividend date
- Shares acquired from this date do not carry the dividend for that period. From this date the shares trade without the right to it.
- Payment date
- The day the confirmed dividend reaches shareholder accounts. It comes weeks to months after the ex-dividend date, and Korean year-end dividends are set only after the shareholder meeting confirms them.
These are the announced ex-dividend and payment dates. The next period is not shown until its dates are set. Days remaining are counted in Korea time when the page was updated, so they can be off by about a day. The dates are copied as announced and can change. For the size of the dividend, see dividend yield. For information only. Not investment advice.
Stocks with similar score profiles
| Stock | Earnings | Financial health | Dividends |
|---|---|---|---|
| Daewoong Pharma (069620, this stock) | 77 | 49 | 43 |
| BDelta Air Lines | 76 | 50 | 42 |
| BBooking Holdings | 72 | 49 | 40 |
| BProgressive | 75 | 55 | 42 |
| BKenvue | 74 | 54 | 46 |
Daewoong Pharma (069620) has category scores of Earnings 77 · Financial health 49 · Dividends 43. These are the four major stocks graded in all three categories whose profiles come closest, and no category differs by more than 6 points.
The three scores are given by Jupick from public financial metrics, each out of 100. A similar profile means similar grading results only. It does not mean the share prices move alike.
Ratios as amounts
Base ₩10,000Every ratio metric of this stock, restated on the same amount. If each line used a different base, the amounts could not be compared, so every line starts from ₩10,000.
For every ₩10,000 of revenue: operating profit ₩1,250.Operating margin 12.5%
- For every ₩10,000 of equityyearly net profit ₩1,700
- If last year's revenue was ₩10,000this year's revenue ₩11,040
- For every ₩10,000 of equitydebt owed ₩10,820
- For every ₩10,000 of debt due within a yearassets turning into cash within a year ₩12,440
- For every ₩10,000 worth of sharesdividends over the last year ₩30
- For every ₩10,000 of net profitdividends paid to shareholders ₩350
- For ₩10,000 of net profitmarket value ₩62,000
- For ₩10,000 of book equitymarket value ₩11,000
The ₩10,000 base is an assumption chosen for easy reading, not this company's actual revenue or equity. The values multiply the ratios shown as they are and round to the nearest won, so they can differ from the source by a few won. Metrics that make no sense as amounts are left out: values that are not measured, values that cannot be confirmed as measured, and loss-making cases where the base amount does not hold.
Metrics that decide the grade
Overall 59 · Grade BThe overall score recalculated with just one of the nine metrics set to the middle score of 50. Only one metric changes at a time, and the other eight stay as they are.
With any single metric at 50, the overall score stays in Grade B.
The metric closest to a boundary is ROE. With only this metric at 50, the overall score would be 53.9, 3.9 points from the 50 point boundary. Earnings · metric 88 · contribution +5.1
The scores above add up this stock's metric scores again with one of them set to 50. They are not new grades, and this stock's grade stays at B. Metric scores and contributions are rounded to one decimal place, so a change within 1 point of a boundary is not reported as a grade change. Changing two or more metrics at once was not calculated.
Where the share price enters the grade
The grade above turns 9 metrics into scores and combines them. Counting how many of them use the share price shows whether the grade moves when the price moves.
The 9 graded metrics stay the same when the share price moves.
- Earnings grade metrics (3)Does not use the share price0 of 3 metrics use the share price
- Financial health grade metrics (3)Does not use the share price0 of 3 metrics use the share price
- Dividends grade metrics (3)Does not use the share price0 of 3 metrics use the share price
- PER and PBRCome from the share price but are not scoredNot graded
For Korean stocks, Dividend yield is taken as stated in the disclosure, so it is not recalculated when the share price changes. What changes the grade is the next financial filing, not the share price.
Stocks with a value for each metric
The grade above uses 9 metrics. Each line shows how many major stocks have a value for that metric, so you can tell whether a blank is specific to this stock or common to most stocks.
8 of the 9 graded metrics have values.
- ROEHas a value567 of 600 stocks have a value
- Operating marginHas a value562 of 600 stocks have a value
- Revenue growthHas a value570 of 600 stocks have a value
- Debt-to-equity ratioHas a value559 of 600 stocks have a value
- Current ratioHas a value545 of 600 stocks have a value
- Interest coverageNot reported278 of 600 stocks have a valueMore than half of stocks have no value
- Dividend yieldHas a value519 of 600 stocks have a value
- Payout ratioHas a value507 of 600 stocks have a value
- Dividend streakHas a value595 of 600 stocks have a value
Blank metrics on this stock: 1. Many other stocks are blank on them too.
Position in the market distribution
Korean stocksWhere the value of Daewoong Pharma sits when the Korean stocks on Jupick are lined up from the smallest value, ignoring sector. Left is smaller, right is larger, and the shaded part is the middle half.
The thin lower axis counts the position again within the same sector (Healthcare) only. 2 of the metrics with a lower axis sit in a different band from the whole market. On those lines, the bracket under the upper axis marks the middle half that the sector's stocks take on the market axis, and the short line inside is their middle.
- PER6.2x
- PBR1.1xOn the upper axis, the middle half of these 32 stocks sits between 62.9% and 94.1%, with the middle at 83.7%.
- ROE17.0%
- Operating margin12.5%
- Debt-to-equity ratio108.2%On the upper axis, the middle half of these 32 stocks sits between 16.8% and 39.9%, with the middle at 28.1%.
- Dividend yield0.3%
Won and dollar stocks have different metric levels, so they are counted in separate samples. This is only where a value sits in a line-up, not a sign of good or bad and not an investment judgement. Stocks without the metric, and loss-making stocks where PER or PBR does not hold, are left out of the sample. The remaining sample size is shown on each line. The sector axis is not drawn when the same-currency, same-sector sample has fewer than 8 stocks.
Korean and US yardsticks
Healthcare sectorWhere one value of Daewoong Pharma sits among Korean stocks in the same sector, and among US stocks. Only ratio metrics that compare across currencies are used.
3 of the 6 compared metrics sit in different bands on the two yardsticks.
- Operating margin 12.5% Korean 30 stocks · upper middle · 60% have a smaller value US 37 stocks · lower middle · 37.8% have a smaller value Gap between yardsticks 22.2 pp
- Dividend yield 0.3% Korean 15 stocks · lowest quarter · 20% have a smaller value US 37 stocks · lower middle · 35.1% have a smaller value Gap between yardsticks 15.1 pp
- ROE 17.0% Korean 32 stocks · highest quarter · 78.1% have a smaller value US 31 stocks · upper middle · 67.7% have a smaller value Gap between yardsticks 10.4 pp
Only metrics with at least 8 stocks on both sides are compared.
Next
Investment notice
For information only. Not investment advice. Grades and figures are reference material calculated from public information. They do not ask anyone to trade a security and make no promise of returns. You are solely responsible for your investment decisions and their results, and Jupick accepts no legal liability for them.